Isoliquiritigenin, a potential therapeutic agent for treatment of inflammation-associated diseases
- PMID: 37604329
- DOI: 10.1016/j.jep.2023.117059
Isoliquiritigenin, a potential therapeutic agent for treatment of inflammation-associated diseases
Abstract
Ethnopharmacological relevance: Licorice is a medicinal herb with a 2000-year history of applications in traditional Chinese medicine. Isoliquiritigenin (ISL) is a bioactive chalcone compound isolated from licorice. It has attracted increasing attention in recent years due to its excellent anti-inflammatory activity.
Aim of the study: This study is to provide a comprehensive summary of the anti-inflammatory activity of ISL and the underlying molecular mechanisms, and discuss new insights for its potential clinical applications as an anti-inflammation agent.
Materials and methods: We examined literatures published in the past twenty years from PubMed, Research Gate, Web of Science, Google Scholar, and SciFinder, with single or combined key words of "isoliquiritigenin", "inflammation", and "anti-inflammatory".
Results: ISL elicits its anti-inflammatory activity by mediating various cellular processes. It inhibits the upstream of the nuclear factor kappa B (NF-κB) pathway and activates the nuclear factor erythroid related factor 2 (Nrf2) pathway. In addition, it suppresses the NOD-like receptor protein 3 (NLRP3) pathway and restrains the mitogen-activated protein kinase (MAPK) pathway.
Conclusions: Current studies indicate a great therapeutical potential of ISL as a drug candidate for treatment of inflammation-associated diseases. However, the pharmacokinetics, biosafety, and bioavailability of ISL remain to be further investigated.
Keywords: Anti-Inflammatory; Inflammation; Isoliquiritigenin; Molecular mechanism.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.
Similar articles
-
The licorice flavonoid isoliquiritigenin attenuates Mycobacterium tuberculosis-induced inflammation through Notch1/NF-κB and MAPK signaling pathways.J Ethnopharmacol. 2022 Aug 10;294:115368. doi: 10.1016/j.jep.2022.115368. Epub 2022 May 16. J Ethnopharmacol. 2022. PMID: 35589023
-
Isoliquiritigenin from licorice flavonoids attenuates NLRP3-mediated pyroptosis by SIRT6 in vascular endothelial cells.J Ethnopharmacol. 2023 Mar 1;303:115952. doi: 10.1016/j.jep.2022.115952. Epub 2022 Nov 25. J Ethnopharmacol. 2023. PMID: 36442759
-
Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.Theranostics. 2019 Jul 9;9(18):5183-5199. doi: 10.7150/thno.33376. eCollection 2019. Theranostics. 2019. PMID: 31410209 Free PMC article.
-
Oncopreventive and Oncotherapeutic Potential of Licorice Chalcone Compounds: Molecular Insights.Mini Rev Med Chem. 2023;23(6):662-699. doi: 10.2174/1389557522666220827161943. Mini Rev Med Chem. 2023. PMID: 36043713 Review.
-
A Review: The Pharmacology of Isoliquiritigenin.Phytother Res. 2015 Jul;29(7):969-77. doi: 10.1002/ptr.5348. Epub 2015 Apr 24. Phytother Res. 2015. PMID: 25907962 Review.
Cited by
-
The Antioxidant Action of Astragali radix: Its Active Components and Molecular Basis.Molecules. 2024 Apr 9;29(8):1691. doi: 10.3390/molecules29081691. Molecules. 2024. PMID: 38675511 Free PMC article. Review.
-
Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway.Pharmaceuticals (Basel). 2023 Dec 27;17(1):43. doi: 10.3390/ph17010043. Pharmaceuticals (Basel). 2023. PMID: 38256877 Free PMC article.
-
A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.Int J Mol Sci. 2024 Nov 11;25(22):12091. doi: 10.3390/ijms252212091. Int J Mol Sci. 2024. PMID: 39596162 Free PMC article.
-
Isoliquiritigenin alleviates radiation-induced intestinal injury in lung cancer by inhibiting TNF-α/caspase3 signaling pathway.Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 26. doi: 10.1007/s00210-025-04007-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40137968
-
Advances in Flavonoid Research: Sources, Biological Activities, and Developmental Prospectives.Curr Issues Mol Biol. 2024 Mar 26;46(4):2884-2925. doi: 10.3390/cimb46040181. Curr Issues Mol Biol. 2024. PMID: 38666911 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous